Related Experiment Video
Updated: Jul 1, 2026
07:03
Large Scale Zebrafish-Based In vivo Small Molecule Screen
Published on: December 30, 2010
14.2K
Phenotypic screening for small molecules that lower PrP in cultured cells
Jeannine A Frei1, Andrew G Reidenbach1, Leo Mh Xu1
1Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Biorxiv : the Preprint Server for Biology
|April 17, 2026
Summary
Researchers screened compounds to lower prion protein (PrP) for prion disease therapy. Two molecules, EYH and LCZ, selectively reduced PrP levels in cells, suggesting a post-translational mechanism, but failed in human cells and in vivo.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Prion protein (PrP) reduction is a therapeutic strategy for prion diseases.
- Phenotypic screening is a method to identify potential drug candidates.
Purpose of the Study:
- To identify small molecules that lower PrP levels using phenotypic screening.
- To assess the specificity and mechanism of action of identified compounds.
Main Methods:
- Phenotypic screening of 3,492 compounds in mouse N2a cells expressing GFP.
- High-content imaging analysis to select compounds reducing PrP without affecting GFP or cell viability.
- Proteomics, mRNA analysis, and co-treatment with proteasome inhibitors to elucidate the mechanism.
Main Results:
- Two compounds, EYH and LCZ, selectively and dose-dependently lowered PrP levels.
- Proteomics revealed PrP as a top downregulated protein; compounds acted post-translationally.
- Compounds showed limited efficacy in human cell lines and failed to reduce PrP in vivo.
Conclusions:
- Mechanism-agnostic phenotypic screening presents challenges for identifying effective PrP-lowering compounds.
- Prioritizing compounds with known mechanisms of action may be more successful for prion disease therapeutics.
